Protalix BioTherapeutics, Inc. PLX
3.13 USD +0.27 (+9.44%)
At closeNov 11, 2026, 5:45 PM EST
3.03 -0.10 -3.24%
After hours · Nov 11, 5:45 PM ET
2.78 Day range 3.14
1.65 52-week range 3.19
- YTD
- +73.89%
- 1 year
- +46.95%
News
seekingalpha.com Protalix BioTherapeutics, Inc. (PLX) Q3 2026 Earnings Call Transcript Protalix BioTherapeutics, Inc. (PLX) Q3 2026 Earnings Call Transcript
benzinga.com Protalix BioTherapeutics Q3 2026 Earnings Call Transcript Protalix BioTherapeutics (AMEX:PLX) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Protalix BioTherapeutics Affirms FY2026 Sales Guidance of $78.000M-$83.000M vs $71.359M Est Protalix BioTherapeutics (AMEX:PLX) affirms FY2026 sales outlook from $78.000 million-$83.000 million to $78.000 million-$83.000 million vs $71.359 million estimate.
prnewswire.com Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results Company to host conference call and webcast today at 8:00 a.m. ET Total revenues increased by $32.0 million year to date to $75.6 million, from $43.6 million for the same period in 2025 Net income…
globenewswire.com Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200 Boys Town National Research Hospital in Nebraska becomes first activated site in study targeting four rare pediatric lysosomal storage disorders and has now initiated patient screening as Polaryx…
benzinga.com Protalix Biotherapeutics To Present Individual Participant Results From PK And PD Analysis Of Higher-Dose Cohorts Of Its Phase 1 Single Ascending Dose Study Of PRX-115, At ACR Convergence 2026 Protalix BioTherapeutics Presents Data Supporting Potential for Less Frequent Dosing in Phase 2 RELEASE Study for Uncontrolled GoutThe Company previously reported that higher single doses of PRX–115…
prnewswire.com Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations Protalix BioTherapeutics Presents Data Supporting Potential for Less Frequent Dosing in Phase 2 RELEASE Study for Uncontrolled Gout The Company previously reported that higher single doses of PRX–115…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Curis (NASDAQ:CRIS) stock moved upwards by 83.5% to $1.31 during Wednesday's pre-market session. The company's market cap stands at $1.7 million. SCWorx (NASDAQ:WORX) stock increased by…
benzinga.com HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $12 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Protalix BioTherapeutics (AMEX:PLX) with a Buy and maintains $12 price target.
benzinga.com Protalix BioTherapeutics Q2 EPS $0.05 Misses $0.12 Estimate, Sales $19.896M Beat $12.931M Estimate Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.12 by 58.33 percent. The company reported quarterly sales of…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market session. The market value of their outstanding shares is at $112.9 million. Barinthus Biotherapeutics…
- benzinga.com CORRECTION: Protalix BioTherapeutics Q1 EPS $0.22 Beats $0.06 Estimate, Sales $33.750M Beat $11.468M Estimate Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.06 by 266.67 percent. This is a 540 percent increase over losses of…
benzinga.com Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call 
benzinga.com Earnings Scheduled For May 13, 2026 
benzinga.com HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $12 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Protalix BioTherapeutics (AMEX:PLX) with a Buy and maintains $12 price target.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Earnings Scheduled For March 18, 2026
- benzinga.com Protalix BioTherapeutics Expects FY26 Total Revenue To Range From ~$78M To $83M Including $25M Milestone Which Protalix Is Entitled To From Chiesi Financial Outlook: Building Durable Growth and Long–Term ValueProtalix enters 2026 with a profitable commercial business through its partnerships and a focused pipeline aligned to areas of high unmet…
- benzinga.com Protalix BioTherapeutics Q4 EPS $(0.06) Misses $0.04 Estimate, Sales $9.300M Miss $16.918M Estimate Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.04 by 250 percent. This is a 166.67 percent decrease over earnings…
- benzinga.com The European Commission Approves 2mg/kg Every-4-weeks Dosing Regimen For Chiesi And Protalix Biotherapeutics' Elfabrio (Pegunigalsidase Alfa) For Fabry Disease Patients Who Are Stable With An Enzyme Replacement Therapy European Commission approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by extending infusion interval frequency from every-two-weeks…
- benzinga.com Chiesi Group's Unit And Protalix BioTherapeutics Say CHMP Of EMA Issues Positive Opinion Recommending Approval Of 2mg/Kg E4W Dosing Regimen For Elfabrio In Fabry Disease Adult Patients Stable With ERT Treatment Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March…
- benzinga.com Earnings Scheduled For November 13, 2025
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Earnings Scheduled For August 14, 2025 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Earnings Scheduled For May 9, 2025
benzinga.com Earnings Scheduled For March 17, 2025 
benzinga.com Earnings Scheduled For November 14, 2024 - benzinga.com Earnings Scheduled For March 14, 2024 Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.
- benzinga.com Earnings Scheduled For November 6, 2023 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
- benzinga.com Earnings Scheduled For August 7, 2023 Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report quarterly loss at $0.44 per share on revenue of $153.69 million.
- benzinga.com Earnings Scheduled For May 4, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
- benzinga.com Earnings Scheduled For November 14, 2022 Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
- benzinga.com Earnings Scheduled For August 15, 2022 Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.
- benzinga.com Earnings Scheduled For May 16, 2022 Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
- benzinga.com Earnings Scheduled For March 31, 2022 Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.
- benzinga.com Earnings Scheduled For November 15, 2021 Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third quarter.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday morning, 282 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday Stocks That Hit 52-Week Lows On Monday Monday morning, 285 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Before 10 a.m. ET on Friday, 29 companies hit new 52-week lows.
- benzinga.com 66 Biggest Movers From Yesterday Gainers
- benzinga.com 40 Stocks Moving In Wednesday's Mid-Day Session Gainers BriaCell Therapeutics Corp. (NASDAQ: BCTX) shares jumped 147.3% to $7.86 after the company provided an update on the overall survival (OS) data on its previously disclosed heavily pretreated…
benzinga.com Earnings Scheduled For May 14, 2021 Companies Reporting Before The Bell • Sogou (NYSE:SOGO) is projected to report earnings for its first quarter. • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its first quarter.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows.
- benzinga.com 30 Stocks Moving In Friday's Mid-Day Session Gainers
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday This morning 533 companies reached new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday On Tuesday, 596 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Monday Monday morning saw 558 companies set new 52-week highs.
- benzinga.com Earnings Scheduled For October 29, 2020 Companies Reporting Before The Bell • PG&E (NYSE:PCG) is likely to report quarterly earnings at $0.27 per share on revenue of $4.72 billion.